TMS for Depression: How Transcranial Magnetic Stimulation Treats Treatment-Resistant Depression
When antidepressants don’t work, the question becomes: what else is there? For the roughly one-third of depression patients who don’t respond adequately to medication, transcranial magnetic stimulation (TMS) offers an answer that doesn’t involve surgery, sedation, or systemic drug side effects. Instead, it uses focused magnetic pulses to wake up underperforming brain circuits, and it works for a significant majority of people who try it.
TMS earned FDA clearance for treatment-resistant depression back in 2008. Since then, the technology has evolved, protocols have gotten faster, and the evidence base has grown substantially. Here is what you need to know about how TMS works, who it helps, and what to realistically expect.
At a Glance
- TMS uses magnetic pulses to stimulate underactive areas of the brain involved in mood regulation, primarily the left dorsolateral prefrontal cortex (DLPFC)
- FDA-cleared for treatment-resistant depression since 2008, with strong clinical evidence from large randomized trials
- Response rates: 50 to 60% of patients respond, and roughly 30% achieve full remission
- Standard protocol: 30 to 36 sessions over 6 to 9 weeks. The accelerated Stanford SAINT protocol compresses treatment into 5 days
- Non-invasive, no sedation required, most common side effect is mild scalp discomfort
- Most insurance plans now cover TMS after documented failure of at least one antidepressant
- Maintenance sessions can help sustain improvement for patients who respond
How TMS Works: The Brain Science
Depression is not simply a “chemical imbalance.” That outdated model has given way to a more accurate understanding: depression involves dysfunctional neural circuits, particularly in the prefrontal cortex and its connections to deeper brain structures that regulate emotion, motivation, and reward.
In many people with depression, the left dorsolateral prefrontal cortex (DLPFC) is underactive. This region plays a critical role in executive function, emotional regulation, and the ability to override negative thought patterns. When it is not firing properly, the brain’s negativity bias runs unchecked, motivation drops, and the cognitive symptoms of depression (poor concentration, indecisiveness, mental fog) take hold.
TMS works by placing an electromagnetic coil against the scalp over the left DLPFC. The coil generates brief magnetic pulses that pass through the skull and induce small electrical currents in the underlying brain tissue. These pulses stimulate neurons in the target area, increasing their activity and strengthening the neural circuits that depression has weakened (1).
Over the course of multiple sessions, this repeated stimulation produces lasting changes in brain function. Neuroimaging studies show that TMS normalizes activity in the DLPFC and improves connectivity between prefrontal regions and deeper mood-regulating structures like the anterior cingulate cortex and the subgenual cingulate (2). The brain essentially relearns healthier patterns of activity.
Who Qualifies for TMS
TMS is specifically indicated for treatment-resistant depression, which typically means you have tried at least one antidepressant at adequate dose and duration without sufficient improvement. Most insurance companies require documentation of this medication failure before approving coverage.
In practice, many TMS candidates have tried multiple medications. Some have tried two, three, or even five or more antidepressants without getting better. TMS offers these patients a fundamentally different approach, one that targets brain circuits directly rather than flooding the entire brain with neurochemical changes.
Good candidates for TMS typically include:
- Adults with major depressive disorder who have not responded to at least one antidepressant
- Patients who cannot tolerate medication side effects (sexual dysfunction, weight gain, emotional blunting)
- People looking for a non-systemic treatment that does not affect the whole body
- Patients willing to commit to the treatment schedule (daily sessions for several weeks)
TMS may not be appropriate for:
- People with metallic implants in or near the head (except titanium dental implants, which are generally safe)
- Patients with a history of seizures or epilepsy (magnetic stimulation can lower seizure threshold)
- People with certain implanted medical devices like cochlear implants or deep brain stimulators
The Standard TMS Protocol
The most established TMS protocol for depression involves repetitive TMS (rTMS) delivered to the left DLPFC at a frequency of 10 Hz. Here is what the treatment course looks like:
Mapping session (first visit). The technician uses the TMS coil to find your motor threshold, the minimum power needed to make your thumb twitch when stimulating the motor cortex. This calibrates the machine to your individual brain. They then use anatomical landmarks or, in more advanced centers, neuronavigation guided by MRI to position the coil over the left DLPFC.
Treatment sessions. You sit in a comfortable chair, fully awake. The coil is positioned against your head. Each session delivers approximately 3,000 magnetic pulses over 19 to 37 minutes (depending on the specific protocol). You hear a clicking sound and feel a tapping sensation on your scalp. Most people describe it as mildly uncomfortable at first but tolerable, and the sensation becomes less noticeable over time.
Treatment course. Standard protocol calls for 5 sessions per week (Monday through Friday) for 6 to 9 weeks, totaling 30 to 36 sessions. After the acute phase, some protocols include a taper period with reduced frequency.
Post-session. You walk out and resume normal activities immediately. There is no sedation, no recovery period, and no cognitive impairment. Many patients schedule sessions during lunch breaks or before work.
Response Rates: What the Evidence Shows
The clinical evidence for TMS in treatment-resistant depression is strong and growing.
The pivotal trial that led to FDA clearance showed that TMS produced a significantly higher remission rate compared to sham treatment. Since then, dozens of randomized controlled trials and large real-world studies have confirmed its efficacy (3).
The numbers from pooled data across major studies:
- Response rate (meaningful improvement): 50 to 60% of patients
- Remission rate (symptoms resolve): approximately 30 to 35%
- Number needed to treat: roughly 4 to 8, meaning for every 4 to 8 patients treated, one additional patient achieves remission compared to sham
These numbers are particularly impressive considering this is a population that has already failed medication. By comparison, switching from one failed antidepressant to another yields a remission rate of only about 15 to 25% (4).
A large naturalistic study (the NeuroStar registry, tracking over 5,000 real-world patients) found even better results: a response rate of about 62% and a remission rate of 41%. This may reflect that real-world treatment allows more clinical flexibility than rigid trial protocols (5).
Accelerated TMS: The Stanford SAINT Protocol
The biggest recent advance in TMS is the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol, also called Stanford Neuromodulation Therapy (SNT). Published in 2022, this approach compresses what normally takes 6 to 9 weeks into just 5 days.
The SAINT protocol differs from standard TMS in several key ways:
- Frequency: 10 sessions per day (50 sessions over 5 days) instead of 1 session per day over weeks
- Targeting: Uses functional MRI to identify the precise spot on each patient’s DLPFC that has the strongest connectivity to the subgenual anterior cingulate cortex (a key depression circuit node), rather than relying on anatomical landmarks alone
- Stimulation pattern: Uses intermittent theta burst stimulation (iTBS), a more efficient pattern that delivers treatment in about 3 minutes per session rather than 19 to 37 minutes
The initial randomized controlled trial reported a remission rate of 79% in the active treatment group, far exceeding standard TMS results. Subsequent studies have shown somewhat lower but still impressive rates, typically 50 to 60% remission (6).
Why SAINT matters: For patients in acute depressive crises, waiting 6 to 9 weeks for standard TMS to work can feel agonizing. The SAINT protocol’s 5-day timeline makes it a much more practical option for severe depression requiring rapid intervention. It is more expensive per course and is currently offered at a limited number of centers, but availability is expanding.
Deep TMS: The BrainsWay H-Coil
Standard TMS uses a figure-8 coil that stimulates relatively superficial brain tissue (about 1.5 to 2 cm deep). Deep TMS, developed by BrainsWay, uses a patented H-coil design that reaches deeper brain structures (about 3 to 4 cm).
BrainsWay’s deep TMS system received FDA clearance for depression in 2013. The broader stimulation pattern may activate a wider network of depression-related circuits. Sessions are typically shorter (about 20 minutes) because the H-coil delivers stimulation more efficiently (7).
Head-to-head comparisons between standard and deep TMS for depression are limited, and both appear effective. The choice often comes down to what equipment is available at your local treatment center.
TMS vs. Medication vs. ECT
| Factor | TMS | Antidepressants | ECT |
|---|---|---|---|
| How it works | Magnetic pulses to left DLPFC | Systemic neurochemical modulation | Electrical current induces controlled seizure |
| Efficacy (treatment-resistant) | 50-60% response, 30% remission | 15-25% remission per switch | 50-70% remission |
| Speed of response | 4-6 weeks (standard), 5 days (SAINT) | 4-8 weeks | 2-4 weeks |
| Side effects | Scalp discomfort, rare headache | Weight gain, sexual dysfunction, emotional blunting, GI issues | Memory loss (often temporary), confusion, requires anesthesia |
| Sedation required | No | No | Yes (general anesthesia) |
| Cognitive effects | None | Possible blunting | Short-term memory impairment common |
| Time commitment | 30-36 daily sessions | Daily pill, indefinite | 6-12 sessions, 2-3x/week |
| Insurance coverage | Good (after failed meds) | Good | Good |
ECT remains the most effective treatment for severe, treatment-resistant depression. But its side effect profile (particularly memory impairment and the need for repeated general anesthesia) makes TMS an attractive first step before considering ECT. Many clinicians now recommend TMS as the next option after medication failure, reserving ECT for cases where TMS also fails or when the depression is too severe to wait (8).
What a TMS Session Actually Feels Like
Patients frequently ask what TMS feels like, so here is a realistic description.
You sit in a padded chair that resembles a dentist’s chair. A technician positions the magnetic coil against the left side of your head, holding it in place with a positioning arm. You are fully awake and alert throughout.
When the machine activates, you hear a rapid clicking sound (like a woodpecker) and feel a tapping or knocking sensation on your scalp. During the first few sessions, most people find this uncomfortable but manageable. The intensity is calibrated to your motor threshold, so it is strong enough to stimulate brain tissue but not painful for most patients. Some describe a mild headache afterward, especially early in treatment, which typically resolves with over-the-counter pain relief.
By the second week, most patients report that the sensation becomes unremarkable. Many read, listen to podcasts, or simply relax during sessions. When the session ends, you stand up and leave. There is no grogginess, no driving restrictions, no need for someone to accompany you.
Improvement typically begins gradually. Many patients notice subtle changes around weeks 2 to 4: better sleep, slightly more motivation, less intense negative thoughts. By the end of the full course, the cumulative effect can be substantial.
Maintenance TMS: Keeping the Benefits
One of the key questions with TMS is: how long do the benefits last? The answer varies by individual, but relapse is a real concern.
Studies tracking patients after initial TMS treatment show that about 50 to 60% of responders maintain their improvement at 12 months. The remainder experience some degree of symptom return. Maintenance TMS, periodic booster sessions after the initial course, can help sustain benefits (9).
Common maintenance schedules include:
- Weekly sessions for a month after the initial course, then tapering to biweekly or monthly
- Symptom-triggered maintenance, where patients come in for a session or short series when they notice early signs of relapse
- Fixed-interval maintenance, such as monthly or every 6 weeks, regardless of symptoms
Many patients also continue antidepressant medication alongside TMS. The combination may provide better long-term stability than either approach alone.
Insurance Coverage and Cost
Insurance coverage for TMS has improved dramatically since initial FDA clearance. Most major insurance plans now cover TMS for treatment-resistant depression, though they typically require:
- A diagnosis of major depressive disorder
- Documentation that at least one (sometimes two or more) antidepressant trials have failed
- Prior authorization
Without insurance, a full course of standard TMS costs approximately $6,000 to $15,000 depending on the provider and region. With insurance, out-of-pocket costs vary but are often limited to copays, which might total $1,000 to $3,000 for the full course.
The accelerated SAINT protocol tends to cost more per course (often $10,000 to $20,000) and has more variable insurance coverage, as it is still considered newer. Some centers are beginning to offer it, and coverage is expanding.
Safety note: TMS has an excellent safety profile. The most serious risk is seizure, which occurs in fewer than 1 in 10,000 sessions. Patients with a history of seizures, certain neurological conditions, or metallic head implants should discuss risks thoroughly with their provider before proceeding. Most patients experience only mild scalp discomfort and occasional headaches that resolve quickly.
Finding a TMS Provider
TMS is available at psychiatric clinics, academic medical centers, and specialized TMS treatment centers across the country. When evaluating providers, consider:
- Experience: How many patients has the clinic treated? Operators who have performed thousands of sessions are preferred
- Equipment: Is it FDA-cleared equipment from a major manufacturer (NeuroStar, BrainsWay, MagVenture)?
- Physician oversight: Is a psychiatrist overseeing your treatment plan, even if technicians deliver individual sessions?
- Targeting method: Does the clinic use MRI-guided neuronavigation, or standard anatomical landmarks?
- Follow-up plan: Does the clinic have a protocol for maintenance sessions and monitoring after the initial course?
The Bottom Line
TMS fills a critical gap in depression treatment. For patients who have not responded to medication, it offers a safe, non-invasive option with meaningful response rates and no systemic side effects. The accelerated SAINT protocol has made the time commitment dramatically more manageable, and insurance coverage continues to improve.
TMS is not a cure-all. Not everyone responds, and those who do may need maintenance treatment. But for the millions of people stuck in treatment-resistant depression, it represents one of the most significant advances in practical, accessible treatment options in the past two decades.
If you have tried antidepressants without success, TMS deserves a serious conversation with your psychiatrist. The evidence supports it, the risks are minimal, and the potential upside is a return to functional, meaningful daily life.
References
- George MS, et al. (2010). Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Archives of General Psychiatry, 67(5), 507-516. doi:10.1001/archgenpsychiatry.2010.46
- Fox MD, et al. (2012). Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biological Psychiatry, 72(7), 595-603. doi:10.1016/j.biopsych.2012.04.028
- O’Reardon JP, et al. (2007). Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biological Psychiatry, 62(11), 1208-1216. doi:10.1016/j.biopsych.2007.01.018
- Rush AJ, et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry, 163(11), 1905-1917. doi:10.1176/ajp.2006.163.11.1905
- Carpenter LL, et al. (2012). Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depression and Anxiety, 29(7), 587-596. doi:10.1002/da.21969
- Cole EJ, et al. (2022). Stanford Accelerated Intelligent Neuromodulation Therapy for treatment-resistant depression. American Journal of Psychiatry, 179(2), 132-141. doi:10.1176/appi.ajp.2021.21060609
- Levkovitz Y, et al. (2015). Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry, 14(1), 64-73. doi:10.1002/wps.20199
- Ren J, et al. (2014). Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: a systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 51, 181-189. doi:10.1016/j.pnpbp.2014.02.004
- Dunner DL, et al. (2014). A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. Journal of Clinical Psychiatry, 75(12), 1394-1401. doi:10.4088/JCP.13m08977
